SPIRIT studies of Taltz show sustained efficacy in psoriatic arthritis.- Eli Lilly

Eli Lilly will share new Taltz (ixekizumab) data from multiple long-term and post-hoc analyses that indicate sustained efficacy in patients with psoriatic arthritis. Lilly will be highlighting notable results from two studies in psoriatic arthritis. In the SPIRIT-P2 study, Taltz demonstrated persistent clearance of nail and skin psoriasis plaques in patients with active psoriatic arthritis, as measured by NAPSI, Psoriasis Area and Severity Index (PASI) and static Physician's Global Assessment (sPGA) responses, for up to three years in patients with prior inadequate response or intolerance to one or two tumor necrosis factor inhibitors (TNFi). In a post-hoc analysis of patients with nail psoriasis at baseline from the SPIRIT-H2H study of TNFi treatment-naïve patients with both active psoriatic arthritis and active psoriasis, 83% of patients treated with Taltz maintained complete resolution of nail psoriasis up to 52 weeks vs. 72% of patients treated with adalimumab (marketed as Humira). In both studies, the safety profile of Taltz was consistent with previously reported results and no unexpected safety signals were found. These studies will be presented at the 29th annual European Academy of Dermatology and Venereology (EADV) Congress, taking place virtually October 29-31, 2020.